C11-SY08
Phase 1Small molecule
C11-SY08 is one of 23 small molecule programs targeting Imaging. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
34 competitors in Imaging
#DrugCompanyPhaseTrials
1Nicorette
PfizerApproved
Ritalin
NovartisApproved
Obicetrapib
NNewAmsterdam Pharma
Phase 3
F-Arag
CCellSight Technologies, Inc.
Phase 2
Hyperpolarized 13c Pyruvate
UUniversity of Maryland, Baltimore
Phase 2
PET Scan With VAT
SStony Brook University
Phase 3
XTR006
SSinotau Pharmaceutical Group
Phase 3
Ga-FAPI-46
UUniversität Münster
Phase 2
Ethanol
RochePreclinical
Ga-HA-DOTATATE
UUniversity of Alberta
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for C11-SY08. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- MMassachusetts General Hospital